메뉴 건너띄기
본문 바로가기 상단메뉴 바로가기

KIST 한국과학기술연구원 Korea Institute of Science and Technology

미투데이 보내기
twitter 보내기
Facebook 보내기
KIST News Board View
Subject KIST Transfers Nanocage Technology to Samyang Biopharmaceuticals (2018.01.16)
Date 2018-01-16 Read 2480
Files

KIST Transfers Nanocage Technology to Samyang Biopharmaceuticals

 

- KIST’s medicinal nano technology selectively attacks cancer cells
- Samyang Biopharmaceuticals is a leading developer of nanocage technology-based treatments

 


On January 16, the Korea Institute of Science and Technology (KIST) and Samyang Biopharmaceuticals signed a technology transfer agreement regarding newly developed nanocage technology and its potential applications. A down payment of KRW 500 million was agreed upon, with a licensing fee of 3%.

 

The team that developed this new technology was led by Dr. Kim In-San of KIST’s Center for Theragnosis. Their antitumor immunity particles not only seek out and destroy cancer cells but also jumpstart the body’s immune system, theoretically deterring cancer cells from recurring or even growing in the first place.

 

These days, countries around the world are actively conducting R&D on antitumor immunity, and the market potential for this research is seemingly great. In fact, the antitumor immunity market, whose size was about USD 1.4 billion in 2014, is expected to reach as high as USD 27.6 billion by 2020.

 

Samyang Biopharmaceuticals’ research currently focuses on DDS-based anticancer drugs, biologics-related pharmaceutical fields, and absorbable material-based medical devices (MD). Because of its technological expertise in pharmaceutics and MD, the company is potentially ripe for overseas expansion.

 

As part of this technology transfer, KIST and Samyang Biopharmaceuticals will work together to verify the usefulness of this new technology before developing new forms of treatment through clinical trials.

 

Samyang Biopharmaceuticals’ president, Mr. Eom Tae-Ung, said, “Samyang Biopharmaceuticals has been engaging in open innovation through active cooperation with other organizations, and the technology transferred by KIST will accelerate our R&D into biologics-related pharmaceutical fields.”

List
KIST News, Previous and Next Contents View
Previous Dr. Kim Soo Hyun Takes Over as President of the Korean Tissue Engineering and Regenerative Medicine Society (2018.01.17)
Next Dr. Cho Won Il Takes Over as President of the Korean Electrochemical Society (2018.01.10)
페이지 만족도 조사

* 열람하신 정보에 대해 만족하십니까?